title: Reproductive performance in the subsequent lactation of dairy cows previously treated for failure to be detected in oestrus.
abstract: OBJECTIVE
  To describe the effect of treatment of cows not detected in oestrus (NDO) with progesterone (P4) and oestradiol benzoate (ODB) in one lactation, on the reproductive and productive performance in the subsequent lactation.
  
  
  METHODS
  Cows (n=770 from nine herds) which were NDO 10 days before the planned start of the seasonal breeding programme (PSM) were blocked by herd, age (2 or >2 years old) and ovarian status (i.e. with or without a palpable corpus luteum; CL), and treated either with an intravaginal progesterone-releasing device and ODB and resynchrony, or were left as untreated controls. In the following lactation, data were collected on the occurrence of endometritis, NDO, breeding dates, pregnancy test results and milk production. The effect of treatment and ovarian status in the previous lactation on the incidence of disease, and the proportions submitted for service, conceived and pregnant in the subsequent lactation were analysed. Calving dates and intervals from start of breeding to first insemination and conception were analysed using Kaplan Meier survival analysis. Additional multivariate analyses were undertaken to include known confounders such as age, breed, herd, calving date and milk production, as well as the cyclic status (i.e. previously cycling, NDO, or "late-calving") in the previous lactation, to examine the potential "carryover" effects of previous status on the reproductive performance in the subsequent lactation.
  
  
  RESULTS
  Treatment of NDO cows resulted in an earlier calving date (Julian calving date 214, 95% CI=207-221, vs 224, 95% CI=220-228; p=0.005), more female calves reared (31.4% vs 23.3%; p=0.01), and reduced risk of being NDO (33.9% vs 46.1%; p=0.002) in the subsequent lactation compared with controls. There were no differences in the incidence of peripartum disease, or the proportion of cows submitted, conceived or pregnant between the Treatment and Control groups in the subsequent lactation (p>0.2). Previously CL-positive (+ve) NDO cows were less likely to produce a female calf that was reared (19.0% vs 29.9%; p=0.005), more likely to be treated as NDO (26.4% vs 18.6%; p=0.02), less likely to conceive by the end of the subsequent lactation's breeding programme (82.2% vs 87.8%; p=0.09), and took longer to conceive (41 vs 33 days from the PSM to conception) than cows that were NDO-CL-negative (-ve) in the previous lactation. There was no interaction between ovarian status and treatment for any of the outcome variables (p>0.05). Cows that were NDO or late-calving in the previous lactation were more likely to be NDO (p<0.005), treated as NDO (p<0.005), and have longer PSM to conception intervals (p<0.005) in the subsequent lactation than cycling herdmates, despite inclusion of factors known to confound reproductive performance in analyses.
  
  
  CONCLUSIONS
  Treatment of NDO cows resulted in more female calves reared, earlier calving and a reduced risk of being NDO in the subsequent lactation. Status (i.e. NDO-CL+ve or NDO-CL-ve) affected some reproductive measures in the subsequent lactation, and the effect of treatment in the subsequent lactation differed between the two groups for some measures. Reproductive performance in the subsequent lactation was not improved despite the earlier calving date and longer calving to PSM intervals. Additionally, the previous season's status was still important in the subsequent season's reproductive performance, despite adjusting for known confounders of fertility.
  
  
  CONCLUSIONS
  The economic benefits from treatment of NDO cows are likely limited to effects of an earlier calving date and potential for longer lactation and increased milk yield, increased number of calves derived from artificial insemination and from a reduced number of NDO cows in the subsequent lactation. Effects of improved reproductive performance in the subsequent lactation were not demonstrated and hence should not be included in any economic analysis of therapy of NDO cows.
authors.affiliation: Animal Health Centre, PO Box 21, Morrinsville, New Zealand. smcdoug@ahc.co.nz
authors.forename: S
authors.initials: S
authors.lastname: McDougall
authors.forename: C
authors.initials: C
authors.lastname: Compton
mesh_terms: D000367:Age Factors; D000780:Anestrus / Q000187:drug effects*; D000818:Animals; D002417:Cattle; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004972:Estrus Detection; D005260:Female; D007774:Lactation / Q000187:drug effects / Q000502:physiology*; D008892:Milk / Q000737:chemistry / Q000378:metabolism; D015999:Multivariate Analysis; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000627:therapeutic use*; D012098:Reproduction / Q000187:drug effects / Q000502:physiology*; D012744:Sex Ratio; D013997:Time Factors
chemical_list: C074283:estradiol 3-benzoate; D011374:Progesterone; D004958:Estradiol